Clinicopathological characteristics of extremely young Korean multiple myeloma patients: Therapeutic implications

Junghoon Shin, Youngil Koh, Jeonghwan Youk, Miso Kim, Byung Soo Kim, Chul Won Choi, Hwa Jung Sung, Yong Park, Sung Soo Yoon, Inho Kim

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Background/Aims: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population. Methods: We reviewed the medical records of MM patients whose age was 40 years or younger at diagnosis. Results: A total of 32 patients were analyzed (male to female ratio 19:13, median age 37 years). According to International Staging System, 29%, 48%, and 16% were in stage I, II, and III, respectively. Light chain myeloma accounted for 30%. Clinically significant anemia, hypercalcemia, azotemia, and hypoalbuminemia were present in 29%, 28%, 13%, and 28%, respectively. Three or more lytic bone lesions were detected in 45% of the patients, whereas 13% had no lytic bone lesions. Regarding treatment, 79% of patients received autologous hematopoietic stem cell transplantation. After a median follow-up duration of 64 months, the 1-, 3-, and 5-year overall survival (OS) rates were 84%, 62%, and 54%, respectively. The median OS was 61 months for the entire cohort. Conclusions: In our study, MM patients aged 40 years or younger at diagnosis showed no superior survival compared to those of the moderately elderly patients based on historical data.

Original languageEnglish
Pages (from-to)722-730
Number of pages9
JournalKorean Journal of Internal Medicine
Issue number4
Publication statusPublished - 2017 Jul
Externally publishedYes


  • Hematopoietic stem cell transplantation
  • Multiple myeloma
  • Treatment outcome
  • Young adult

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Clinicopathological characteristics of extremely young Korean multiple myeloma patients: Therapeutic implications'. Together they form a unique fingerprint.

Cite this